Edesa Biotech (NASDAQ:EDSA – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.25, Zacks reports.
Edesa Biotech Trading Up 7.6 %
Shares of EDSA traded up $0.14 during mid-day trading on Friday, reaching $1.94. 26,998 shares of the company’s stock were exchanged, compared to its average volume of 15,515. Edesa Biotech has a 52-week low of $1.69 and a 52-week high of $5.99. The company has a 50-day simple moving average of $2.91 and a two-hundred day simple moving average of $3.94.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Edesa Biotech in a research note on Tuesday, August 20th.
About Edesa Biotech
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.
Recommended Stories
- Five stocks we like better than Edesa Biotech
- What Do S&P 500 Stocks Tell Investors About the Market?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Stock Sentiment Analysis: How it Works
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
